Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 7/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7878018 | 0.90 | ADORA2A (0.52) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL7874381 | 0.89 | ADORA2A (0.78) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL17423151 | 0.86 | KMT2A (0.57) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL18231328 | 0.84 | ADORA2A (0.52) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| Trifluoroacetic Acid SCHEMBL7960593 | 0.82 | ADORA2A (0.67) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL7875783 | 0.81 | ACHE (0.63) | MBNL1BCHEACHE | |
| SCHEMBL29375789 | 0.81 | ADORA2A (0.83) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL7875793 | 0.81 | ADORA2A (0.83) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| SCHEMBL7875727 | 0.79 | MEN1 (0.56) | ADORA2AMEN1KMT2ATDP1MBNL1 | |
| Trifluoroacetic Acid SCHEMBL30227214 | 0.79 | ADORA2A (0.53) | ADORA2AMEN1KMT2ATDP1MBNL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-6242459-B1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-06-05 | — | — | US | disclosed |
| EP-0979078-A4 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-0979078-A1 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998030218-A1 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | CCR5, CCR2, CCR1 | ADORA2A 116/4885MEN1 4216/4885KMT2A 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.